De-stabilization of the positive vago-vagal reflex in bulimia nervosa

Physiology and Behavior

Volumn 94, Issue 1, 2008, Pages 136-153

  Faris, Patricia L ^a   Hofbauer, Randall D ^a   Daughters, Randall ^a   VandenLangenberg, Erin ^a   Iversen, Laureen ^a   Goodale, Robert L ^a   Maxwell, Robert ^a   Eckert, Elke D ^a   Hartman, Boyd K ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

De stabilization of positive feedbacks; Pathophysiology of bulimia nervosa; Vagus nerves

Indexed keywords

ANTIDEPRESSANT AGENT; ANTINEOPLASTIC AGENT; CHOLECYSTOKININ; FLUOXETINE; ONDANSETRON; PLACEBO; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ARTICLE; BEHAVIOR THERAPY; BULIMIA; CLINICAL TRIAL; COGNITIVE THERAPY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; FEEDBACK SYSTEM; HEALTH CARE COST; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOTHERAPY; SATIETY; VAGUS NERVE STIMULATION; VOMITING;

EID: 41849108384     PISSN: 00319384     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.physbeh.2007.11.036     Document Type: Article

References (87)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. (1994), American Psychiatric Association, Washington, D.C.
2. Fairburn C.G. Evidence-based treatment of anorexia nervosa. Int J Eat Disord 37 (2005) S26-S30
3. Fernandes M., Atallah A.N., Soares B.G.O., Humberto S., Guimaraes S., Matos D., et al. Intragastric balloon for obesity. Cochrane Database Syst Rev 24 (2007) CD004931
4. Stefano S.C., Bacaltchuk J., Blay S.L., and Hay P. Self-help treatments for disorders of recurrent binge eating: a systematic review. Acta Psychiatr Scand 113 (2006) 452-459
5. Mitchell J.E., Agras S., and Wonderlich S. Treatment of bulimia nervosa: where are we and where are we going?. Int J Eat Disord 40 (2007) 95-101
6. Halmi K.A., Agras W.S., Mitchell J., Wilson G.T., Crow S., Bryson S.W., et al. Relapse predictors of patients with bulimia nervosa who achieved abstinence through cognitive behavioral therapy. Arch Gen Psychiatry 59 (2002) 1105-1109
7. Mcgilley B.M., and Pryor T.L. Assessment and treatment of bulimia nervosa. Am Fam Phys 57 (1998) 2743-2750
8. Striegel-Moore R.H., Leslie D., Petrill S.A., Garvin V., and Rosenheck R.A. One-year use and cost of inpatient and outpatient services among female and male patients with an eating disorder: evidence from a national database of health insurance claims. Int J Eat Disord 27 (2000) 381-389
9. Spoor T.P., Stice E., Burton E., and Bohon C. Relations of bulimic symptom frequency and intensity to psychosocial impairment and health care utilization: results from a community-recruited sample. Int J Eat Disord 40 (2007) 505-514
10. In: Lynne D. (Ed). Life and death tug of war: the whole Terri Schiavo story. World Net Daily (2005). http://www.worldnetdaily.com www.worldnetdaily.com, March 24
11. Mitchell J.E., and Groat R. A placebo-controlled, double-blind trial of amitriptyline in bulimia. J Clin Psychopharmacol 4 (1984) 186-193
12. Goldstein D.J., Wilson M.G., Thompson V.L., Potvin J.H., and Rampey Jr. A.H. Long-term fluoxetine treatment of bulimia nervosa. Fluoxetine Bulimia Nervosa Research Group. Br. J Psychiatry 166 (1995) 660-666
13. Fichter M.M., Leibl C., Kruger R., and Rief W. Effects of fluvoxamine on depression, anxiety, and other areas of general psychopathology in bulimia nervosa. Pharmacopsychiatry 30 (1997) 85-92
14. Mitchell J.E., Halmi K., Wilson G.T., Agras W.S., Kraemer H., and Crow S. A randomized secondary treatment study of women with bulimia nervosa who fail to respond to CBT. Int J Eat Disord 32 (2002) 271-281
15. Walsh B.T., Fairburn C.G., Mickley D., Sysko R., and Parids M.K. Treatment of bulimia nervosa in a primary care setting. Am J Psychiatry 161 (2004) 556-561
16. Brewerton T.D. Toward a unified theory of serotonin dysregulation in eating and related disorders. Psychoneuroendocrinology 20 (1995) 561-590
17. Blackshaw L.A., and Grundy D. Effects of 5-hydroxytryptamine on discharge of vagal mucosal afferent fibres from the upper gastrointestinal tract of the ferret. J Auton Nerv Syst 45 (1993) 41-50
18. Steiger H., Gauvin L., Engelberg M.J., Ying Kin N.M., Israel M., Wonderlich S.A., et al. Mood- and restraint-based antecedents to binge episodes in bulimia nervosa: possible influences of the serotonin system. Psychol Med 35 (2005) 1553-1562
19. Miller K.R. Finding Darwin's God: a scientist's search for common ground between God and Evolution (2007), Harper Perennial
20. Halmi K.A., and Sunday S.R. Temporal patterns of hunger and fullness ratings and related cognitions in anorexia and bulimia. Appetite 16 (1991) 219-237
21. Hadigan C.M., Walsh B.T., Devlin M.J., LaChaussee J.L., and Kissileff H.R. Behavioral assessment of satiety in bulimia nervosa. Appetite 18 (1992) 233-241
22. Kissileff H.R., Wentzlaff T.H., Guss J.L., Walsh B.T., Devlin M.J., and Thornton J.C. A direct measure of satiety disturbance in patients with bulimia nervosa. Physiol Behav 60 (1996) 1077-1085
23. Geracioti Jr. T.D., and Liddle R.A. Impaired cholecystokinin secretion in bulimia nervosa. N Engl J Med 319 (1988) 683-688
24. Weigert N., Li Y.Y., Schick R.R., Coy D.H., Classen M., and Schusdziarra V. Role of vagal fibers and bombesin/gastrin-releasing peptide-neurons in distention-induced gastrin release in rats. Regul Pept 69 (1997) 33-40
25. Phillips R.J., and Powley T.L. Gastric volume detection after selective vagotomies in rats. Am J Physiol 274 (1998) R1626-R1638
26. Schwartz G.J., Netterville L.A., McHugh P.R., and Moran T.H. Gastric loads potentiate inhibition of food intake produced by a cholecystokinin analogue. Am J Physiol 261 (1991) R1141-R1146
27. Grundy D. Signalling the state of the digestive tract. Auton Neurosci 125 (2006) 76-80
28. Kissileff H.R., Carretta J.C., Geliebter A., and Pi-Sunyer F.X. Cholecystokinin and stomach distension combine to reduce food intake in humans. Am J Physiol 285 (2003) R992-R998
29. Zafra M.A., Molina F., and Puerto A. The neural/cephalic phase reflexes in the physiology of nutrition. Neurosci Biobehav Rev 30 (2006) 1032-1044
30. Ritter R.C. Gastrointestinal mechanisms of satiation for food. Physiol Behav 81 (2004) 249-273
31. Moran T.H., Ladenheim E.E., and Schwartz G.J. Within-meal gut feedback signaling. Int J Obes Relat Metab Disord 25 (2001) 539-541
32. Arakawa T., Uno H., Fukuda T., Higuchi K., and Kuroki T. New aspects of gastric adaptive relaxation, reflex after food intake for more food: involvement of capsaicin-sensitive sensory nerves and nitric oxide. J Smooth Muscle Res 33 (1997) 81-88
33. Berthoud H.R., and Patterson L.M. Anatomical relationship between vagal afferent fibers and CCK-immunoreactive entero-endocrine cells in the rat small intestinal mucosa. Acta Anat (Basel) 156 (1996) 123-131
34. Schwartz G.J., and Moran T.H. Sub-diaphragmatic vagal afferent integration of meal-related gastrointestinal signals. Neurosci Biobehav Rev 20 (1996) 47-56
35. Van de Wall E.H., Duffy P., and Ritter R.C. CCK enhances response to gastric distension by acting on capsaicin-insensitive vagal afferent. Am J Physiol, Regul Integr Comp Physiol 389 (2005) R695-R703
36. Peters J.H., McKay B.M., Simasko S.M., and Ritter R.C. Leptin-induced satiation mediated by abdominal vagal afferents. Am J Physiol, Regul Integr Comp Physiol 288 (2005) R879-R884
37. Hayes M.R., Savastano D.M., and Covasa M. Cholecystokinin-induced satiety is mediated through interdependent cooperation of CCK-A and 5-HT3 receptors. Physiol Behav 82 (2004) 663-669
38. Smith G.P. Animal models of human eating disorders. Ann N Y Acad Sci 575 (1989) 63-72
39. Kondo D.G., and Sokol M.S. Eating disorders in primary care. Postgrad Med 119 (2006) 59-65
40. Stephan E., Pardo J.V., Faris P.L., Hartman B.K., Kim S.W., Ivanov E.H., et al. Functional neuroimaging of gastric distention. J Gastrointest Surg 7 (2003) 740-749
41. Freeman A.J., Cunningham K.T., and Tyers M.B. Selectivity of 5-HT3 receptor antagonists and anti-emetic mechanisms of action. Anticancer Drugs 3 (1992) 79-85
42. Gibbs J., Young R.C., and Smith G.P. Cholecystokinin decreases food intake in rats. J Comp Physiol Psychol 84 (1973) 488-495
43. Woods S.C. Gastrointestinal satiety signals I. An overview of gastrointestinal signals that influence food intake. Am J Physiol: Gastrointest Liver Physiol 286 (2004) G7-G13
44. Verbalis J.G., Richardson D.W., and Stricker E.M. Vasopressin release in response to nausea-producing agents and cholecystokinin in monkeys. Am J Physiol 252 (1987) R749-R753
45. Mazda T., Yamamoto H., Fujimura M., and Fujimiya M. Gastric distention-induced release of serotonin stimulates c-fos expression in specific brain nuclei via 5-HT3 receptors in conscious rats. Am J Physiol: Gastrointest Liver Physiol 287 (2003) G228-G235
46. Gulley S., Sharma S.K., Moran T.H., and Sayegh A.I. Cholecystokinin-8 increases Fos-like immunoreactivity in the brainstem and myenteric neurons of rats through the CCK(1) receptors. Peptides 26 (2005) 1617-1622
47. Daughters R.S., Hartman B.K., Grossman A.W., Marshall A.M., and Faris P.L. Ondansetron attenuates CCK-induced satiety and c-fos labeling in the dorsal medulla. Peptides 22 (2001) 1331-1338
48. Faris P.L., Raymond N.C., De Zwaan M., Howard L.A., Eckert E.D., and Mitchell J.E. Nociceptive, but not tactile, thresholds are elevated in bulimia nervosa. Biol Psychiatry 32 (1992) 462-466
49. Randich A., and Maixner W. [D-Ala]methionine enkephalin-amide reflexively induces antinociception by activating vagal afferents. Pharmacol Biochem Behav 21 (1984) 441-448
50. Ren K., Randich A., and Gebhart G.F. Electrical stimulation of cervical vagal afferents. I. Central relays for modulation of spinal nociceptive transmission. J Neurophysiol 64 (1990) 1098-1114
51. Lautenbacher S., Pauls A.M., Strian F., Pirke K.M., and Krieg J.C. Pain sensitivity in anorexia nervosa and bulimia nervosa. Biol Psychiatry 29 (1991) 1-6
52. de Zwaan M., Biener D., Schneider C., and Stacher G. Relationship between thresholds to thermally and to mechanically induced pain in patients with eating disorders and healthy subjects. Pain 67 (1996) 511-512
53. Girdler S.S., Koo-Loeb J., Pedersen C.A., Brown H.J., and Maixner W. Blood pressure-related hypoalgesia in bulimia nervosa. Psychosom Med 60 (1998) 736-743
54. Moran T.H., and McHugh P.R. Cholecystokinin suppresses food intake by inhibiting gastric emptying. Am J Physiol 242 (1982) R491-R497
55. Murialdo G., Casu M., Falchero M., Brugnolo A., Patrone V., Cerro P.F., et al. Alterations in the autonomic control of heart rate variability in patients with anorexia or bulimia nervosa: correlations between sympathovagal activity, clinical features, and leptin level. J Endocrinol Invest 30 (2007) 356-362
56. Rissanen A., Naukkarinen H., Virkkunen M., Rawlings R.R., and Linnoila M. Fluoxetine normalizes increased cardiac vagal tone in bulimia nervosa. J Clin Psychopharmacol 18 (1998) 26-32
57. Geliebter A., Melton P.M., McCray R.S., Gallagher D.R., Gage D., and Hashim S.A. Gastric capacity, gastric emptying, and test-meal intake in normal and bulimic women. Am J Clin Nutr 56 (1992) 656-661
58. Devlin M.J., Walsh B.T., Guss J.L., Kissileff H.R., Liddle R.A., and Petkova E. Postprandial cholecystokinin release and gastric emptying in patients with bulimia nervosa. Am J Clin Nutr 65 (1997) 114-120
59. Faris P.L., Kim S.W., Meller W.H., Goodale R.L., Hofbauer R.D., Oakman S.A., et al. Effect of ondansetron, a 5 HT3 receptor antagonist, on the dynamic association between bulimic behaviors and pain thresholds. Pain 77 (1998) 297-303
60. Hedeker D. MIXREG: a Fortran program for mixed-effects linear regression models (1993), Prevention Research Center, University of Illinois at Chicago, Chicago
61. Faris P.L., Kim S.W., Meller W.H., Goodale R.L., Oakman S.A., Hofbauer R.D., et al. Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa: a randomised, double-blind trial. Lancet 355 (2000) 792-797
62. Galligan J.J. Electrophysiological studies of 5-hydroxytryptamine receptors on enteric neurons. Behav. Brain Res 73 (1996) 199-201
63. Simpson K.H., Murphy P., Colthup P.V., and Whelan P. Concentration of ondansetron in cerebrospinal fluid following oral dosing in volunteers. Psychopharmacology (Berl) 109 (1992) 497-498
64. Schinkel A.H., Wagenaar E., and van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest (1996) 972517-972524
65. Reynolds D.J., Barber N.A., Grahame S.D., and Leslie R.A. Cisplatin-evoked induction of c-fos protein in the brainstem of the ferret: the effect of cervical vagotomy and the anti-emetic 5-HT3 receptor antagonist granisetron (BRL 43694). Brain Res 565 (1991) 231-236
66. Fukui H., Yamamoto M., and Sato S. Vagal afferent fibers and peripheral 5-HT3 receptors mediate cisplatin-induced emesis in dogs. Jpn J Pharmacol 59 (1992) 221-226
67. Li Y., Hao Y., Zhu J., and Owyang C. Serotonin released from intestinal enterochromaffin cells mediates luminal non-cholecystokinin-stimulated pancreatic secretion in rats. Gastroenterology 118 (2000) 1997-2207
68. Zhu J.X., Zhu X.Y., Owyang C., and Li Y. Intestinal serotonin acts as a paracrine substance to mediate vagal signal transmission evoked by luminal factors in the rat. J Physiol 530 (2001) 431-442
69. Hatton K.W., McLarney J.T., Pittman T., and Fahy B.G. Vagal nerve stimulation: overview and implications for anesthesiologists. Anesth Analg 103 (2006) 1241-1249
70. Rush A.J., George M.S., Sackeim H.A., Marangell L.B., Husain M.M., Giller C., et al. Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multi-center study. Biol Psychiatry 47 (2000) 276-286
71. Rennie D. How to report randomised controlled trials: the CONSORT statement. JAMA 276 (1996) 649
72. Rinaman L., Card J.P., Schwaber J.S., and Miselis R.R. Ultrastructural demonstration of a gastric monosynaptic vagal circuit in the nucleus of the solitary tract in rat. J Neurosci 9 (1989) 1985-1996
73. Cinquin O., and Demongeot J. Roles of positive and negative feedback in biological systems. C R Biol 325 (2002) 1085-1095
74. Brunton L.L. A positive feedback loop contributes to the deleterious effects of angiotensin. Proc Natl Acad Sci U S A 102 (2005) 14483-14484
75. Robertson D.S. Feedback theory and Darwinian evolution. J Theor Biol 152 (1991) 469-484
76. Ding B., Abe J., Wei H., Xu H., Che W., Aizawa T., et al. A positive feedback loop of phosphodiesterase 3 (PDE3) and inducible cAMP early repressor (ICER) leads to cardiomyocyte apoptosis. Proc Natl Acad Sci U S A 102 (2005) 14771-14776
77. Angeli D., Ferrell Jr. J.E., and Sontag E.D. Detection of multistability, bifurcations, and hysteresis in a large class of biological positive-feedback systems. Proc Natl Acad Sci U S A 101 (2004) 1822-1827
78. Faris P.L., Eckert E.D., Kim S.W., Meller W.H., Pardo J.V., Goodale R.L., et al. Evidence for a vagal pathophysiology for bulimia nervosa and the accompanying depressive symptoms. J. Affect Disord 92 (2006) 79-90
79. Lehrman D.S. Ethology and psychology. Recent Adv Biol Psychiatry 4 (1961) 86-94
80. Lehrman D.S., and Wortis R.P. Previous breeding experience and hormone-induced incubation behavior in the ring dove. Science 132 (1960) 1667-1668
81. Kim S.W., Grant J.E., Eckert E.D., Faris P.F., and Hartman B.K. Pathological gambling and mood disorders: clinical associations and treatment implications. J Affect Disorders 92 (2006) 109-116
82. Kim S.W. Opioid antagonists in the treatment of impulse-control disorders. J Clin Psychiatry 59 (1998) 159-164
83. Zheng H., Kelly L., Patterson S.M., and Berthoud H.R. Effect of brain stem NMDA-receptor blockade by MK-801 on behavioral and fos responses to vagal satiety signals. Am J Physiol 277 (1999) R1104-R1111
84. Mitchell J.E., de Zwann M., and Roerig J.L. Drug therapy for patients with eating disorders. Curr Drug Targets CNS Neurol Disord 2 (2003) 17-29
85. Marrazzi M.A., Kinzie J., and Luby E.D. A detailed longitudinal analysis on the use of naltrexone in the treatment of bulimia. Int. Clin. Psychopharmacol. 10 (1995) 173-176
86. Kim S.W., Grant J.E., Yoon G., Williams K.A., and Remmel R.P. Safety of high-dose naltrexone treatment: hepatic transaminase profiles among outpatient. Clin Neuropharmacol. 29 (2006) 77-79
87. Wilson G.T., Loeb K.L., Walsh B.T., Labouvie E., Petkova L., Liu X., et al. Psychological versus pharmacological treatments of bulimia nervosa: predictors and processes of change. J Consult Clin Psychol 67 (1999) 451-459